By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galectin Therapeutics 

7 Wells Avenue
Suite #34
Newton  Massachusetts  02459  U.S.A.
Phone: 617-559-0033 Fax: 617-928-3450


Company News
Galectin (GALT)’s GR-MD-02 Demonstrates Efficacy In Patients With Moderate To Severe Plaque Psoriasis 3/6/2017 8:40:00 AM
Galectin (GALT) Stock Craters After Phase IIa NASH Failure 9/28/2016 5:55:29 AM
Galectin Reports Second Quarter 2016 Financial Results And Provides Business Update 8/9/2016 8:39:19 AM
Peter G. Traber, M.D., CEO And CMO Of Galectin, To Speak On The Medical Applications Of Plant-Derived Complex Carbohydrates 7/13/2016 10:24:15 AM
Galectin Receives Notice Of Australian Patent To Be Granted For The Use Of GR-MD-02 In Liver, Kidney, Lung Or Heart Fibrosis 7/12/2016 10:14:04 AM
Galectin Announces Pricing Of $9.8 Million Registered Direct Offering 11/20/2015 7:59:44 AM
Research Underlying Galectin's Development Of GR-MD-02 In Cancer Presented At The Society For Immunotherapy Of Cancer Annual Meeting 11/11/2015 8:04:31 AM
Galectin Reports Third Quarter 2015 Financial Results And Provides Business Update 11/9/2015 9:05:21 AM
Galectin Selected To Present At Cavendish Global Health Impact Forum 10/23/2015 8:09:39 AM
Galectin' GR-MD-02 To Be Studied In Combination With Keytruda In Patients With Metastatic Melanoma 10/19/2015 7:29:53 AM